Navigation Links
Publication of Shire plc's Annual Report 2008
Date:3/25/2009

the Company's filings with the Securities and Exchange Commission.

    APPENDIX
    1. Principal Risks and Uncertainties
    RISKS RELATED TO THE GROUP'S BUSINESS
    The Group's new products may not be a commercial success

Shire has launched a number of new products in the last four years, including key new products ELAPRASE, VYVANSE, LIALDA, FIRAZYR and FOSRENOL (Rest of World ('ROW')). The commercial success of these new products, as well as other new products that the Group may launch in the future, will depend on their approval and acceptance by physicians, patients and other key decision-makers, as well as the timing of the receipt of marketing approvals, the scope of marketing approvals as reflected in the product's label, the countries in which such approvals are obtained, the authorization of price and reimbursement in those countries where price and reimbursement is negotiated, and safety, efficacy, convenience and cost-effectiveness of the product as compared to competitive products.

The Group may not be able to grow revenues in its new products as quickly as anticipated if any or all of the following occur:

    - if competitive products are genericised and the impact on the market
      negatively affects the prescribing of branded treatments for the
      indications that the Group's new products treat;

    - if there are unanticipated adverse events experienced with the Group's
      new products not seen in clinical trials that impact the physician's
      willingness to prescribe the Group's new products;

    - if issues arise from clinical trials being conducted for post marketing
      purposes or for registration in another country or regulatory agencies
      in one country act in a way that causes concern for prescribers or
      patients in another country;

    - if patients, payors or physicians favor older treatments over newer
      treatments;

    -
'/>"/>
SOURCE  Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 

Related biology technology :

1. Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM)
2. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
3. InVitria Among Leading Innovators in Cell Culture Media According to Top Biotechnology Publication
4. BioTrends Releases TreatmentTrends(TM): US Nephrology, an Ongoing Syndicated Publication Providing Insight into Physician Perceptions and Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
5. New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases
6. PharmSource and BioProcess Technology Consultants Announce Publication of New Market Report: Cell Culture Manufacturing Capacity: Trends and Outlook through 2013
7. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
8. Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated
9. Publication on Tregitopes in Blood Journal of October 2008
10. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
11. ABMAC Foundation Announces Publication of an Historic Volume Documenting the Creation of a National Health Care System in Taiwan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... Bed bug cases tend to increase during summer. And ... risk of becoming the pests' next victim throughout the season, ... the guide, the company enumerated the steps of getting ... , According to My Cleaning Products, there are two ... during summer: the warm weather and the rise in travel. ...
(Date:5/24/2013)... 2013 The Oklahoma tornado left ... ravage, the mayor of Moore, one of the heavily damaged ... a report from cnn.com. Reaching out to also be of ... and Safe Shield to counter the looming mold problem. , ... May 22, 2013, caused 24 deaths, My Cleaning Products shared. ...
(Date:5/23/2013)... 2013 Venaxis, Inc. (Nasdaq:   APPY), an ... FDA clearance and commercializing its rapid, protein biomarker-based appendicitis ... an underwritten public offering of 10,000,000 shares of its ... of its common stock at an exercise price of ... of $1.25 per share and related warrant.  Venaxis has ...
(Date:5/23/2013)... , May 23, 2013 PuraMed BioScience ... and marketer of over-the-counter (OTC) medicinal and healthcare ... opinion on the company based on low market ... , Non-Prescription, All Natural Product to Treat Migraine ... Outperforms #1 Prescription Competitor , Currently Available ...
Breaking Biology Technology:Steps for Getting Rid of Bed Bugs without Using Chemicals and Avoiding Them While Traveling Enumerated by My Cleaning Products in Its Latest Post 2Steps for Getting Rid of Bed Bugs without Using Chemicals and Avoiding Them While Traveling Enumerated by My Cleaning Products in Its Latest Post 3Mayor of Oklahoma-Tornado-Impaired Town Proposes Storm Shelter Bill, My Cleaning Products Offers Complimentary Molderizer and Safe Shield to Help Victim with Looming Mold 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3
... EDT , EAST BRUNSWICK, N.J., May 6 Savient Pharmaceuticals, ... the three months ended March 31, 2009. For the first ... million, or $0.41 per basic and diluted share, on total revenues ... or $0.33 per basic and diluted share on total revenues of ...
... Therapeutics (Nasdaq: NKTR ) today reported its financial ... loss for the quarter ended March 31, 2009 was $31.8 ... $40.7 million or $0.44 per share in the first quarter ... efficiencies as compared to a year ago. Total operating costs ...
... U.S. President Bill Clinton will,participate as one of the main ... 1 and 3 in Sao Paulo, Brazil. The event is ... of the most,important gatherings focused on biofuels in the world. ... Democratic president awarded a second term,in six decades. After leaving ...
Cached Biology Technology:Savient Pharmaceuticals Reports First Quarter 2009 Financial Results 2Savient Pharmaceuticals Reports First Quarter 2009 Financial Results 3Savient Pharmaceuticals Reports First Quarter 2009 Financial Results 4Savient Pharmaceuticals Reports First Quarter 2009 Financial Results 5Savient Pharmaceuticals Reports First Quarter 2009 Financial Results 6Savient Pharmaceuticals Reports First Quarter 2009 Financial Results 7Savient Pharmaceuticals Reports First Quarter 2009 Financial Results 8Savient Pharmaceuticals Reports First Quarter 2009 Financial Results 9Nektar Therapeutics Reports First Quarter 2009 Financial Results 2Nektar Therapeutics Reports First Quarter 2009 Financial Results 3Nektar Therapeutics Reports First Quarter 2009 Financial Results 4Nektar Therapeutics Reports First Quarter 2009 Financial Results 5Nektar Therapeutics Reports First Quarter 2009 Financial Results 6Nektar Therapeutics Reports First Quarter 2009 Financial Results 7Nektar Therapeutics Reports First Quarter 2009 Financial Results 8Nektar Therapeutics Reports First Quarter 2009 Financial Results 9President Bill Clinton to Speak at the Ethanol Summit in Brazil 2
(Date:5/23/2013)... or harsh treatments because science fails to identify ... the disease. Researchers at Case Western Reserve University ... that allows patients to safely choose to do ... drastic measures. , The project is one of ... engineering at Case Western Reserve and director of ...
(Date:5/23/2013)... the team reveal the interplay of brain chemicals which ... Wellcome Trust and BBSRC. , By changing the ... perceptual abilities. While these changes can affect the strength ... fidelity of that response. , Lead author ... communicate with others, you can make yourself better heard ...
(Date:5/22/2013)... have developed a novel technique that can detect molecular ... that is one of the most important, though time-consuming, ... a paper in Nature , post-doctoral researcher David ... Schnell of the Center for Free-Electron Laser Science (CFEL) ... finely-tuned microwave fields to identify molecular variants apart, and ...
Breaking Biology News(10 mins):Using big data to identify prostate cancers and best treatments 2Using big data to identify prostate cancers and best treatments 3Detecting mirror molecules 2Detecting mirror molecules 3
... discovered how the toxoplasmosis parasite may trigger the development ... from the University of Leeds, Faculty of Biological Sciences ... role in the development of these disorders by affecting ... messages in the brain controlling aspects of movement, cognition ...
... University Life Sciences researchers have discovered a new mechanism ... cells, which could lead to the development of a ... is transmitted to humans through bites from mosquitoes. According ... 350 million and 500 million cases of malaria occur ...
... Strosberg of Scripps Florida, was published on March 4, 2009, ... edition, Papers in Press. In the new study, ... more amino acids) derived from the core protein of hepatitis ... dimerization of the core protein (the joining of two identical ...
Cached Biology News:Research supports toxoplasmosis link to schizophrenia 2Researchers identify new way the malaria parasite and red blood cells interact 2Scripps research team identifies key molecules that inhibit viral production 2Scripps research team identifies key molecules that inhibit viral production 3
Recognizes Kir4.1. The epitope does not share homology with any other known proteins.,SPECIES REACTIVITIES: The antibody is also expected to work with mouse and human due to sequence homology. Oth...
... This DuoSet ELISA Development kit contains ... of sandwich ELISAs to measure natural and ... culture supernates and serum. Each kit contains ... fifteen 96-well plates, provided that the following ...
HIV-1 TAT (vN-21)...
Presenilin-1, N-terminus....
Biology Products: